Management of hypertension

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Hypertension is managed using lifestyle modification and antihypertensive medications. Hypertension is usually treated to achieve a blood pressure of below 140/90 mmHg to 160/100 mmHg. According to one 2003 review, reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.[1]

Blood pressure target[edit]

For most people, recommendations are to reduce blood pressure to less than or equal to somewhere between 140/90 mmHg to 160/100 mmHg.[2][3] Attempting to achieve lower levels have not been shown to improve outcomes[3] while there is evidence that it increases side effects.[4] In those with diabetes or kidney disease some recommend levels below 120/80 mmHg;[2][5] however, evidence does not support these lower levels.[3][6]

The benefit of medications is related to a person's cardiac disease risk.[7] Evidence for medications in those with mild hypertension (between 140/90 mmHg and 160/100 mmHg) and no other health problems is less clear with some reviews finding no benefit[8] and other reviews finding benefit.[9] A 2012 Cochrane review found medications for mild hypertension did not reduce the risk of death, stroke, or cardiovascular disease, but did cause side effects in 1 of every 12 people.[8][10] A second review that looked at higher risk people (mostly diabetics whose blood pressure was difficult to control) found the medication prevented a stroke for 1 in every 223 and death for 1 in every 110 who took them.[10] If there are benefits to treating people with mild hypertension they appear to occur primarily among those at highest risk, though all groups experience side effects at a similar rate (1 in 12).[10] Medications are not recommended for people with prehypertension or high normal blood pressure.[11]

If the blood pressure goal is not met, a change in treatment should be made as therapeutic inertia is a clear impediment to blood pressure control.[12]

Lifestyle modifications[edit]

The first line of treatment for hypertension is identical to the recommended preventive lifestyle changes[13] and includes dietary changes,[14] physical exercise, and weight loss. These have all been shown to significantly reduce blood pressure in people with hypertension.[15] Their potential effectiveness is similar to and at times exceeds a single medication.[11] If hypertension is high enough to justify immediate use of medications, lifestyle changes are still recommended in conjunction with medication.[citation needed]

Dietary change, such as a low sodium diet and a vegetarian diet are beneficial. A long term (more than 4 weeks) low sodium diet is effective in reducing blood pressure, both in people with hypertension and in people with normal blood pressure.[16] Also, the DASH diet, a diet rich in nuts, whole grains, fish, poultry, fruit and vegetables lowers blood pressure.[17] A major feature of the plan is limiting intake of sodium, although the diet is also rich in potassium, magnesium, calcium, as well as protein.[17] A vegetarian diet is associated with a lower blood pressure and switching to such a diet may be useful for reducing high blood pressure.[18] A review in 2012 found that a diet high in potassium lowers blood pressure in those with high blood pressure and may improve outcomes in those with normal kidney function,[19] while a 2006 review found evidence to be inconsistent; additionally, the review found no significant reduction in blood pressure overall for people with high blood pressure who were given oral potassium supplementation.[20] Meta-analyses conducted by the Cochrane Hypertension group have found no evidence of an appreciable blood pressure reduction from any combination of calcium, magnesium or potassium supplements; this information stands contrary to prior systematic reviews suggesting that a dietary intake adjustment for each of these may benefit adults with high blood pressure.[21][22][23] While weight loss diets reduce body weight and blood pressure, it is unclear if they reduce negative outcomes.[14]

Some programs aimed to reduce psychological stress such as biofeedback or transcendental meditation may be reasonable add-ons to other treatment to reduce hypertension.[24] However several techniques, namely yoga, relaxation and other forms of meditation do not appear to reduce blood pressure,[25] and there are major methodological limitations with many studies of stress reduction techniques.[26] There is no clear evidence that the modest reduction in blood pressure with stress reduction techniques results in prevention of cardiovascular disease.[25][26]

Several exercise regimes—including isometric resistance exercise, aerobic exercise, resistance exercise, and device-guided breathing—may be useful in reducing blood pressure.[25]

Medications[edit]

Several classes of medications, collectively referred to as antihypertensive medications, are available for treating hypertension. Use should take into account the person's cardiovascular risk (including risk of myocardial infarction and stroke) as well as blood pressure readings, in order to gain a more accurate picture of the person's risks.[2]

Thiazide diuretic

The best first-line medication is disputed,[27] but the Cochrane collaboration, World Health Organization and the United States guidelines support low-dose thiazide-based diuretic as first-line treatment.[15][27][28][29] The UK guidelines emphasise calcium channel blockers (CCB) in preference for people over the age of 55 years or if of African or Caribbean family origin, with angiotensin-converting enzyme inhibitors (ACE-I) used first line for younger people.[30] In Japan starting with any one of six classes of medications including: CCB, ACEI/ARB, thiazide diuretics, beta-blockers, and alpha-blockers is deemed reasonable, while in Canada and Europe all of these but alpha-blockers are recommended as options.[11][27] When compared to placebo, beta-blockers have greater benefit in stroke reduction, but no difference on coronary heart disease or all-cause mortality.[31] However, three-quarters of active beta-blocker treatment in the randomised controlled trials included in the review were with atenolol and none with the newer vasodilating beta-blockers.[32]

Medication combinations[edit]

The majority of people require more than one medication to control their hypertension. In those with a systolic blood pressure greater than 160 mmHg or a diastolic blood pressure greater than 100 mmHg the American Heart Association recommends starting both a thiazide and an ACEI, ARB or CCB.[15] An ACEI and CCB combination can be used as well.[15] In general, medications should be implemented in a stepped care approach when people do not reach target blood pressure levels.[33]

Unacceptable combinations are non-dihydropyridine calcium blockers (such as verapamil or diltiazem) and beta-blockers, dual renin–angiotensin system blockade (e.g. angiotensin converting enzyme inhibitor + angiotensin receptor blocker), renin–angiotensin system blockers and beta-blockers, beta-blockers and centrally acting medications.[34] Combinations of an ACE-inhibitor or angiotensin II–receptor antagonist, a diuretic and an NSAID (including selective COX-2 inhibitors and non-prescribed medications such as ibuprofen) should be avoided whenever possible due to a high documented risk of acute kidney failure. The combination is known colloquially as a "triple whammy" in the Australian health industry.[13] Tablets containing fixed combinations of two classes of medications are available and while convenient for the people, may be best reserved for those who have been established on the individual components.[35] Additionally, the use of treatments with vasoactive agents for people with pulmonary hypertension with left heart disease or hypoxemic lung diseases may cause harm and unnecessary expense.[36]

Elderly[edit]

Treating moderate to severe hypertension decreases death rates and cardiovascular morbidity and mortality in people aged 60 and older.[37] The recommended BP goal is advised as <150/90 mm Hg with thiazide diuretic, CCB, ACEI, or ARB being the first line medication in the United States,[38] and in the revised UK guidelines calcium-channel blockers are advocated as first line with targets of clinic readings <150/90, or <145/85 on ambulatory or home blood pressure monitoring.[30]

There are no randomized clinical trials addressing the goal blood pressure of hypertensives over 79 years old. A recent review concluded that antihypertensive treatment reduced cardiovascular deaths and disease, but did not significantly reduce total death rates.[37] Two professional organizations have published guidelines for the management of hypertension in persons over 79 years old.[39][40]

Resistant hypertension[edit]

Resistant hypertension is defined as hypertension that remains above goal blood pressure in spite of using, at once, three antihypertensive medications belonging to different drug classes. Guidelines for treating resistant hypertension have been published in the UK[41] and US.[42] It has been proposed that a proportion of resistant hypertension may be the result of chronic high activity of the autonomic nervous system; this concept is known as "neurogenic hypertension".[43] Low adherence to treatment is an important cause of resistant hypertension.[44]

Research[edit]

Non-drug treatment[edit]

One avenue of research investigating more effective treatments for severe resistant hypertension has focused on the use of selective radiofrequency ablation. It employs a catheter-based device to cause thermal injury to the sympathetic nerves surrounding the renal arteries, with the aim to reduce renal sympathetic overactivity (so-called "renal denervation") and thereby reduce blood pressure. It has been employed in clinical trials for resistant hypertension.[45] However, a prospective, single-blind, randomized, sham-controlled clinical trial failed to confirm a beneficial effect.[46] Infrequent renal artery dissection, femoral artery pseudoaneurysm, excessive decreases in blood pressure and heart rate have been reported.[45] A 2014 consensus statement from The Joint UK Societies recommended radiofrequency ablation not be used for the treatment of resistant hypertension,[47] but supported continuing clinical trials. Patient selection, with attention to measurement of pre- and post-procedure sympathetic nerve activity and norepinephrine levels, may help differentiate responders from non-responders to this procedure.[48]

Although considered an experimental treatment in the United States and the United Kingdom, it is an approved treatment in Europe, Australia, and Asia.[49][50]

Pregnancy[edit]

Regarding research in hypertension that occurs during pregnancy, it has been recommended that basic research be directed toward increasing understanding of the genetics and pathogenesis of oxidative stress in preeclampsia; and that clinical trials be initiated to assess which interventions are effective in preventing oxidative stress during pregnancy. Regarding the management of essential hypertension in the woman who becomes pregnant, the recommendation is that clinical trials be initiated to assess the effectiveness of various medication regimens, and their effect on mother and fetus.[51]

2017 guidelines[edit]

The American Heart Association and the American College of Cardiology issued guidelines on November 13, 2017 based on the findings of the Systolic Blood Pressure Intervention Trial (SPRINT) a large randomized trial published in November 2015 looking at systolic blood pressure targets of 140 and 120 mmHg among persons with at least 130 mmHg systolic blood pressure, increased cardiovascular risk, and no diabetes.[52][53][54] The lower target was associated with a 0.5% annual absolute decrease in cardiovascular episodes and all-cause mortality (relative risk 0.75), but also an increased rate of serious adverse events.[55] Also the method of blood pressure measurement in SPRINT differed from that used for standard office blood pressure. The method used by SPRINT typically gives a 5-10mmHg lower estimate of blood pressure, and this may need to be taken into account when setting blood pressure targets.[56]

References[edit]

  1. ^ Law M, Wald N, Morris J; Wald; Morris (2003). "Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy" (PDF). Health Technol Assess. 7 (31): 1–94. doi:10.3310/hta7310. PMID 14604498. Archived from the original (PDF) on 2011-03-04.
  2. ^ a b c Nelson, Mark. "Drug treatment of elevated blood pressure". Australian Prescriber (33): 108–112. Archived from the original on 26 August 2010. Retrieved 11 August 2010.
  3. ^ a b c Arguedas, JA; Perez, MI; Wright, JM (Jul 8, 2009). Arguedas, Jose Agustin, ed. "Treatment blood pressure targets for hypertension". Cochrane Database of Systematic Reviews (3): CD004349. doi:10.1002/14651858.CD004349.pub2. PMID 19588353.
  4. ^ "Treating blood pressure between 140/90 and 160/95 mmHg: no proven benefit". Prescrire Int. 23 (148): 106. April 2014. PMID 24860904.
  5. ^ Shaw, Gina (2009-03-07). "Prehypertension: Early-stage High Blood Pressure". WebMD. Retrieved 3 July 2009.
  6. ^ Arguedas, JA; Leiva, V; Wright, JM (Oct 30, 2013). "Blood pressure targets for hypertension in people with diabetes mellitus". The Cochrane Database of Systematic Reviews. 10 (10): CD008277. doi:10.1002/14651858.cd008277.pub2. PMID 24170669.
  7. ^ Blood Pressure Lowering Treatment Trialists', Collaboration; Sundström, J; Arima, H; Woodward, M; Jackson, R; Karmali, K; Lloyd-Jones, D; Baigent, C; Emberson, J; Rahimi, K; MacMahon, S; Patel, A; Perkovic, V; Turnbull, F; Neal, B (Aug 16, 2014). "Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data". Lancet. 384 (9943): 591–8. doi:10.1016/s0140-6736(14)61212-5. PMID 25131978.
  8. ^ a b Diao, D; Wright, JM; Cundiff, DK; Gueyffier, F (Aug 15, 2012). "Pharmacotherapy for mild hypertension". The Cochrane Database of Systematic Reviews (Submitted manuscript). 8 (8): CD006742. doi:10.1002/14651858.CD006742.pub2. PMID 22895954.
  9. ^ Sundström, Johan; Arima, Hisatomi; Jackson, Rod; Turnbull, Fiona; Rahimi, Kazem; Chalmers, John; Woodward, Mark; Neal, Bruce (February 2015). "Effects of Blood Pressure Reduction in Mild Hypertension". Annals of Internal Medicine. 162 (3): 184–91. doi:10.7326/M14-0773. PMID 25531552.
  10. ^ a b c Green, Gary (August 21, 2015). "Treatment of Mild Hypertension for the Primary Prevention of Cardiovascular Events". theNNT. Retrieved 24 August 2015.
  11. ^ a b c Giuseppe, Mancia; Fagard, R; Narkiewicz, K; Redon, J; Zanchetti, A; Bohm, M; Christiaens, T; Cifkova, R; De Backer, G; Dominiczak, A; Galderisi, M; Grobbee, DE; Jaarsma, T; Kirchhof, P; Kjeldsen, SE; Laurent, S; Manolis, AJ; Nilsson, PM; Ruilope, LM; Schmieder, RE; Sirnes, PA; Sleight, P; Viigimaa, M; Waeber, B; Zannad, F; Redon, J; Dominiczak, A; Narkiewicz, K; Nilsson, PM; et al. (July 2013). "2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". European Heart Journal. 34 (28): 2159–219. doi:10.1093/eurheartj/eht151. PMID 23771844.
  12. ^ Eni C. Okonofua; Kit N. Simpson; Ammar Jesri; Shakaib U. Rehman; Valerie L. Durkalski; Brent M. Egan (January 23, 2006). "Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals". Hypertension. 47 (2006, 47:345): 345–51. doi:10.1161/01.HYP.0000200702.76436.4b. PMID 16432045. Retrieved 22 November 2009.
  13. ^ a b "NPS Prescribing Practice Review 52: Treating hypertension". NPS Medicines Wise. September 1, 2010. Archived from the original on 22 February 2011. Retrieved 5 November 2010.
  14. ^ a b Semlitsch, Thomas; Jeitler, Klaus; Berghold, Andrea; Horvath, Karl; Posch, Nicole; Poggenburg, Stephanie; Siebenhofer, Andrea (2016-03-02). "Long-term effects of weight-reducing diets in people with hypertension". The Cochrane Database of Systematic Reviews. 3: CD008274. doi:10.1002/14651858.CD008274.pub3. ISSN 1469-493X. PMID 26934541.
  15. ^ a b c d Go, AS; Bauman, M; King, SM; Fonarow, GC; Lawrence, W; Williams, KA; Sanchez, E (Nov 15, 2013). "An Effective Approach to High Blood Pressure Control: A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention". Hypertension. 63 (4): 878–885. doi:10.1161/HYP.0000000000000003. PMID 24243703.
  16. ^ He, Feng J.; Li, Jiafu; Macgregor, Graham A. (2013-04-30). "Effect of longer-term modest salt reduction on blood pressure". The Cochrane Database of Systematic Reviews (4): CD004937. doi:10.1002/14651858.CD004937.pub2. ISSN 1469-493X. PMID 23633321.
  17. ^ a b "Your Guide To Lowering Your Blood Pressure With DASH" (PDF). Retrieved 8 June 2009.
  18. ^ Yokoyama, Yoko; Nishimura, Kunihiro; Barnard, Neal D.; Takegami, Misa; Watanabe, Makoto; Sekikawa, Akira; Okamura, Tomonori; Miyamoto, Yoshihiro (2014). "Vegetarian Diets and Blood Pressure". JAMA Internal Medicine. 174 (4): 577–87. doi:10.1001/jamainternmed.2013.14547. ISSN 2168-6106. PMID 24566947.
  19. ^ Aburto, NJ; Hanson, S; Gutierrez, H; Hooper, L; Elliott, P; Cappuccio, FP (3 April 2013). "Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses". BMJ (Clinical Research Ed.). 346: f1378. doi:10.1136/bmj.f1378. PMC 4816263. PMID 23558164.
  20. ^ Dickinson, HO; Nicolson, DJ; Campbell, F; Beyer, FR; Mason, J (19 July 2006). "Potassium supplementation for the management of primary hypertension in adults". The Cochrane Database of Systematic Reviews (3): CD004641. doi:10.1002/14651858.CD004641.pub2. PMID 16856053.
  21. ^ Dickinson, HO; Nicolson, DJ; Campbell, F; Cook, JV; Beyer, FR; Ford, GA; Mason, J (19 July 2006). "Magnesium supplementation for the management of essential hypertension in adults". The Cochrane Database of Systematic Reviews (3): CD004640. doi:10.1002/14651858.CD004640.pub2. PMID 16856052.
  22. ^ Dickinson, HO; Nicolson, DJ; Cook, JV; Campbell, F; Beyer, FR; Ford, GA; Mason, J (19 April 2006). "Calcium supplementation for the management of primary hypertension in adults". The Cochrane Database of Systematic Reviews (2): CD004639. doi:10.1002/14651858.CD004639.pub2. PMID 16625609.
  23. ^ Beyer, FR; Dickinson, HO; Nicolson, DJ; Ford, GA; Mason, J (19 July 2006). "Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults". The Cochrane Database of Systematic Reviews (3): CD004805. doi:10.1002/14651858.CD004805.pub2. PMID 16856060.
  24. ^ National Clinical Guideline Centre (UK) (2011). "Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34". PMID 22855971.
  25. ^ a b c Brook, RD; Appel, LJ; Rubenfire, M; Ogedegbe, G; Bisognano, JD; Elliott, WJ; Fuchs, FD; Hughes, JW; Lackland, DT; Staffileno, BA; Townsend, RR; Rajagopalan, S; American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical, Activity (Jun 2013). "Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the american heart association". Hypertension. 61 (6): 1360–83. doi:10.1161/HYP.0b013e318293645f. PMID 23608661.
  26. ^ a b Nagele, Eva; Jeitler, Klaus; Horvath, Karl; Semlitsch, Thomas; Posch, Nicole; Herrmann, Kirsten H.; Grouven, Ulrich; Hermanns, Tatjana; Hemkens, Lars G.; Siebenhofer, Andrea (2014). "Clinical effectiveness of stress-reduction techniques in patients with hypertension". Journal of Hypertension. 32 (10): 1936–1944. doi:10.1097/HJH.0000000000000298. ISSN 0263-6352. PMID 25084308.
  27. ^ a b c Klarenbach, SW; McAlister, FA, Johansen, H, Tu, K, Hazel, M, Walker, R, Zarnke, KB, Campbell, NR, Canadian Hypertension Education, Program (May 2010). "Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension". The Canadian Journal of Cardiology. 26 (5): e158–63. doi:10.1016/S0828-282X(10)70383-4. PMC 2886561. PMID 20485695.
  28. ^ James, PA.; Oparil, S.; Carter, BL.; Cushman, WC.; Dennison-Himmelfarb, C.; Handler, J.; Lackland, DT.; Lefevre, ML.; et al. (Dec 2013). "2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–20. doi:10.1001/jama.2013.284427. PMID 24352797.
  29. ^ Wright, James M.; Musini, Vijaya M.; Gill, Rupam (April 2018). "First-line drugs for hypertension". The Cochrane Database of Systematic Reviews. 4: CD001841. doi:10.1002/14651858.CD001841.pub3. ISSN 1469-493X. PMC 80673. PMID 29667175.
  30. ^ a b National Institute Clinical Excellence (August 2011). "1.5 Initiating and monitoring antihypertensive drug treatment, including blood pressure targets". GC127 Hypertension: Clinical management of primary hypertension in adults. Archived from the original on 10 January 2012. Retrieved 23 December 2011.
  31. ^ Wiysonge, Charles S.; Bradley, Hazel A.; Volmink, Jimmy; Mayosi, Bongani M.; Opie, Lionel H. (20 Jan 2017). "Beta-blockers for hypertension". The Cochrane Database of Systematic Reviews. 1: CD002003. doi:10.1002/14651858.CD002003.pub5. ISSN 1469-493X. PMC 5369873. PMID 28107561.
  32. ^ Opie, LH; Wiysonge, CS (Feb 26, 2014). "β-Blocker therapy for patients with hypertension--reply". JAMA: The Journal of the American Medical Association. 311 (8): 862–3. doi:10.1001/jama.2014.336. PMID 24570254.
  33. ^ Glynn, Liam G; Murphy, Andrew W; Smith, Susan M; Schroeder, Knut; Fahey, Tom (2010-03-17). "Cochrane Database of Systematic Reviews". Cochrane Database of Systematic Reviews (3): CD005182. doi:10.1002/14651858.cd005182.pub4. PMID 20238338.
  34. ^ Sever PS, Messerli FH; Messerli (October 2011). "Hypertension management 2011: optimal combination therapy". Eur. Heart J. 32 (20): 2499–506. doi:10.1093/eurheartj/ehr177. PMID 21697169.
  35. ^ "2.5.5.1 Angiotensin-converting enzyme inhibitors". British National Formulary. No. 62. September 2011.
  36. ^ American College of Chest Physicians; American Thoracic Society (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American College of Chest Physicians and American Thoracic Society, retrieved 6 January 2013
  37. ^ a b Musini VM, Tejani AM, Bassett K, Wright JM; Tejani; Bassett; Wright (2009). Musini, Vijaya M, ed. "Pharmacotherapy for hypertension in the elderly". Cochrane Database of Systematic Reviews (4): CD000028. doi:10.1002/14651858.CD000028.pub2. PMID 19821263.
  38. ^ James, Paul A.; Oparil, Suzanne; Carter, Barry L.; Cushman, William C.; Dennison-Himmelfarb, Cheryl; Handler, Joel; Lackland, Daniel T.; LeFevre, Michael L.; MacKenzie, Thomas D.; Ogedegbe, Olugbenga; Smith, Sidney C.; Svetkey, Laura P.; Taler, Sandra J.; Townsend, Raymond R.; Wright, Jackson T.; Narva, Andrew S.; Ortiz, Eduardo (18 December 2013). "2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults". JAMA. 311 (5): 507–20. doi:10.1001/jama.2013.284427. PMID 24352797.
  39. ^ Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force (May 2011). "ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents". Circulation. 123 (21): 2434–506. doi:10.1161/CIR.0b013e31821daaf6. PMID 21518977.
  40. ^ Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members (July 2013). "2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". Journal of Hypertension. 31 (7): 1281–357. doi:10.1097/01.hjh.0000431740.32696.cc. PMID 23817082.
  41. ^ "CG34 Hypertension - quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 28 June 2006. Archived from the original (PDF) on 13 March 2009. Retrieved 4 March 2009.
  42. ^ Calhoun DA, Jones D, Textor S, et al. (June 2008). "Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research". Hypertension. 51 (6): 1403–19. doi:10.1161/HYPERTENSIONAHA.108.189141. PMID 18391085.
  43. ^ Zubcevic J, Waki H, Raizada MK, Paton JF; Waki; Raizada; Paton (June 2011). "Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension". Hypertension. 57 (6): 1026–33. doi:10.1161/HYPERTENSIONAHA.111.169748. PMC 3105900. PMID 21536990.
  44. ^ Santschi, V; Chiolero, A; Burnier, M (Nov 2009). "Electronic monitors of drug adherence: tools to make rational therapeutic decisions". Journal of Hypertension. 27 (11): 2294–5, author reply 2295. doi:10.1097/hjh.0b013e328332a501. PMID 20724871.
  45. ^ a b Gulati, V.; White, WB. (August 2013). "Review of the state of renal nerve ablation for patients with severe and resistant hypertension". J Am Soc Hypertens. 7 (6): 484–93. doi:10.1016/j.jash.2013.07.003. PMC 3855181. PMID 23953998.
  46. ^ Bhatt, Deepak L.; Kandzari, David E.; O'Neill, William W.; D'Agostino, Ralph; Flack, John M.; Katzen, Barry T.; Leon, Martin B.; Liu, Minglei; Mauri, Laura; Negoita, Manuela; Cohen, Sidney A.; Oparil, Suzanne; Rocha-Singh, Krishna; Townsend, Raymond R.; Bakris, George L. (2014). "A Controlled Trial of Renal Denervation for Resistant Hypertension". New England Journal of Medicine. 370 (15): 1393–1401. doi:10.1056/NEJMoa1402670. ISSN 0028-4793. PMID 24678939.
  47. ^ Lobo, M. D.; de Belder, M. A.; Cleveland, T.; Collier, D.; Dasgupta, I.; Deanfield, J.; Kapil, V.; Knight, C.; Matson, M.; Moss, J.; Paton, J. F. R.; Poulter, N.; Simpson, I.; Williams, B.; Caulfield, M. J. (2014). "Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension". Heart. 101 (1): 10–16. doi:10.1136/heartjnl-2014-307029. ISSN 1355-6037. PMC 4283620. PMID 25431461.
  48. ^ Kaplan's Clinical Hypertension, 2010, page 51.
  49. ^ Kaplan's Clinical Hypertension, 2015, p 45
  50. ^ Schmieder, RE; Redon, J; Grassi, G; Kjeldsen, SE; Mancia, G; Narkiewicz, K; Parati, G; Ruilope, L; van de Borne, P; Tsioufis, C (May 2012). "ESH position paper: renal denervation - an interventional therapy of resistant hypertension". Journal of Hypertension. 30 (5): 837–41. doi:10.1097/HJH.0b013e328352ce78. PMID 22469838.
  51. ^ Roberts, J. M.; Pearson, G.; Cutler, J.; Lindheimer, M. (10 February 2003). "Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy". Hypertension. 41 (3): 437–445. doi:10.1161/01.HYP.0000054981.03589.E9. PMID 12623940.
  52. ^ "Just Released—The 2017 Hypertension Clinical Practice Guidelines Read the latest recommendations that will change the way high blood pressure is evaluated and managed". Hypertension. November 2017. Retrieved November 18, 2017.
  53. ^ Paul K. Whelton, Robert M. Carey, Wilbert S. Aronow, Donald E. Casey Jr., Karen J. Collins, Cheryl Dennison Himmelfarb, Sondra M. DePalma, Samuel Gidding, Kenneth A. Jamerson, Daniel W. Jones, Eric J. MacLaughlin, Paul Muntner, Bruce Ovbiagele, Sidney C. Smith Jr., Crystal C. Spencer, Randall S. Stafford, Sandra J. Taler, Randal J. Thomas, Kim A. Williams Sr., Jeff D. Williamson and Jackson T. Wright Jr. (November 2017). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Journal of the American College of Cardiology. 71 (19): e127–e248. doi:10.1016/j.jacc.2017.11.006. PMID 29146535. Retrieved November 18, 2017.
  54. ^ Gina Kolata (November 13, 2017). "Under New Guidelines, Millions More Americans Will Need to Lower Blood Pressure". The New York Times. Retrieved November 18, 2017.
  55. ^ Sprint Research, Group; Wright Jr, J. T.; Williamson, J. D.; Whelton, P. K.; Snyder, J. K.; Sink, K. M.; Rocco, M. V.; Reboussin, D. M.; Rahman, M; Oparil, S; Lewis, C. E.; Kimmel, P. L.; Johnson, K. C.; Goff Jr, D. C.; Fine, L. J.; Cutler, J. A.; Cushman, W. C.; Cheung, A. K.; Ambrosius, W. T. (2015). "A Randomized Trial of Intensive versus Standard Blood-Pressure Control". New England Journal of Medicine. 373 (22): 2103–16. doi:10.1056/NEJMoa1511939. PMC 4689591. PMID 26551272.
  56. ^ Bakris, George L. (2016-09-27). "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 134 (13): 904–905. doi:10.1161/CIRCULATIONAHA.116.022536. ISSN 0009-7322. PMID 27576778.